vs
EVI INDUSTRIES, INC.（EVI）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是EVI INDUSTRIES, INC.的1.8倍（$207.3M vs $115.3M），EVI INDUSTRIES, INC.净利率更高（2.1% vs -62.0%，领先64.1%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 24.4%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 17.2%）
EVI Industries是一家商用洗衣、干洗及衣物护理设备的领先分销商，主要服务北美市场，客户涵盖自助洗衣店、酒店、医疗机构及多户住宅物业，同时提供设备安装、维护及售后支持服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
EVI vs RARE — 直观对比
营收规模更大
RARE
是对方的1.8倍
$115.3M
营收增速更快
RARE
高出1.5%
24.4%
净利率更高
EVI
高出64.1%
-62.0%
两年增速更快
RARE
近两年复合增速
17.2%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $115.3M | $207.3M |
| 净利润 | $2.4M | $-128.6M |
| 毛利率 | 30.8% | — |
| 营业利润率 | 3.7% | -54.7% |
| 净利率 | 2.1% | -62.0% |
| 营收同比 | 24.4% | 25.9% |
| 净利润同比 | 109.9% | 3.5% |
| 每股收益（稀释后） | $0.15 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EVIRARE
| Q4 25 | $115.3M | $207.3M | ||
| Q3 25 | $108.3M | $159.9M | ||
| Q2 25 | $110.0M | $166.5M | ||
| Q1 25 | $93.5M | $139.3M | ||
| Q4 24 | $92.7M | $164.6M | ||
| Q3 24 | $93.6M | $139.5M | ||
| Q2 24 | $90.1M | $147.0M | ||
| Q1 24 | $84.0M | $108.8M |
净利润EVIRARE
| Q4 25 | $2.4M | $-128.6M | ||
| Q3 25 | $1.8M | $-180.4M | ||
| Q2 25 | $2.1M | $-115.0M | ||
| Q1 25 | $1.0M | $-151.1M | ||
| Q4 24 | $1.1M | $-133.2M | ||
| Q3 24 | $3.2M | $-133.5M | ||
| Q2 24 | $2.1M | $-131.6M | ||
| Q1 24 | $956.0K | $-170.7M |
毛利率EVIRARE
| Q4 25 | 30.8% | — | ||
| Q3 25 | 31.3% | — | ||
| Q2 25 | 30.8% | — | ||
| Q1 25 | 30.0% | — | ||
| Q4 24 | 29.7% | — | ||
| Q3 24 | 30.8% | — | ||
| Q2 24 | 30.4% | — | ||
| Q1 24 | 30.7% | — |
营业利润率EVIRARE
| Q4 25 | 3.7% | -54.7% | ||
| Q3 25 | 3.3% | -106.9% | ||
| Q2 25 | 3.7% | -64.8% | ||
| Q1 25 | 2.4% | -102.6% | ||
| Q4 24 | 2.6% | -74.3% | ||
| Q3 24 | 5.3% | -94.6% | ||
| Q2 24 | 4.1% | -79.1% | ||
| Q1 24 | 2.9% | -151.9% |
净利率EVIRARE
| Q4 25 | 2.1% | -62.0% | ||
| Q3 25 | 1.7% | -112.8% | ||
| Q2 25 | 1.9% | -69.0% | ||
| Q1 25 | 1.1% | -108.5% | ||
| Q4 24 | 1.2% | -80.9% | ||
| Q3 24 | 3.5% | -95.7% | ||
| Q2 24 | 2.3% | -89.5% | ||
| Q1 24 | 1.1% | -156.8% |
每股收益（稀释后）EVIRARE
| Q4 25 | $0.15 | $-1.28 | ||
| Q3 25 | $0.11 | $-1.81 | ||
| Q2 25 | $0.14 | $-1.17 | ||
| Q1 25 | $0.07 | $-1.57 | ||
| Q4 24 | $0.07 | $-1.34 | ||
| Q3 24 | $0.21 | $-1.40 | ||
| Q2 24 | $0.13 | $-1.52 | ||
| Q1 24 | $0.06 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $144.0M | $-80.0M |
| 总资产 | $315.6M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EVIRARE
| Q4 25 | — | $421.0M | ||
| Q3 25 | $4.7M | $202.5M | ||
| Q2 25 | $8.9M | $176.3M | ||
| Q1 25 | $5.9M | $127.1M | ||
| Q4 24 | $3.9M | $174.0M | ||
| Q3 24 | $4.4M | $150.6M | ||
| Q2 24 | $4.6M | $480.7M | ||
| Q1 24 | $3.3M | $112.3M |
总债务EVIRARE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $24.0M | — | ||
| Q4 24 | $27.9M | — | ||
| Q3 24 | $19.9M | — | ||
| Q2 24 | $12.9M | — | ||
| Q1 24 | $21.9M | — |
股东权益EVIRARE
| Q4 25 | $144.0M | $-80.0M | ||
| Q3 25 | $140.8M | $9.2M | ||
| Q2 25 | $143.5M | $151.3M | ||
| Q1 25 | $140.2M | $144.2M | ||
| Q4 24 | $138.0M | $255.0M | ||
| Q3 24 | $136.1M | $346.8M | ||
| Q2 24 | $136.6M | $432.4M | ||
| Q1 24 | $133.5M | $140.3M |
总资产EVIRARE
| Q4 25 | $315.6M | $1.5B | ||
| Q3 25 | $321.8M | $1.2B | ||
| Q2 25 | $307.0M | $1.3B | ||
| Q1 25 | $251.8M | $1.3B | ||
| Q4 24 | $248.8M | $1.5B | ||
| Q3 24 | $245.5M | $1.5B | ||
| Q2 24 | $230.7M | $1.6B | ||
| Q1 24 | $239.3M | $1.3B |
负债/权益比EVIRARE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.17× | — | ||
| Q4 24 | 0.20× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 1.70× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流EVIRARE
| Q4 25 | $4.0M | $-99.8M | ||
| Q3 25 | $1.0M | $-91.4M | ||
| Q2 25 | $9.9M | $-108.3M | ||
| Q1 25 | $9.1M | $-166.5M | ||
| Q4 24 | $2.0M | $-79.3M | ||
| Q3 24 | $207.0K | $-67.0M | ||
| Q2 24 | $12.4M | $-77.0M | ||
| Q1 24 | $9.4M | $-190.7M |
自由现金流EVIRARE
| Q4 25 | — | $-100.8M | ||
| Q3 25 | $-890.0K | $-92.7M | ||
| Q2 25 | $8.2M | $-110.7M | ||
| Q1 25 | $8.1M | $-167.8M | ||
| Q4 24 | $1.1M | $-79.5M | ||
| Q3 24 | $-1.0M | $-68.6M | ||
| Q2 24 | $11.2M | $-79.0M | ||
| Q1 24 | $8.1M | $-193.9M |
自由现金流率EVIRARE
| Q4 25 | — | -48.6% | ||
| Q3 25 | -0.8% | -58.0% | ||
| Q2 25 | 7.5% | -66.5% | ||
| Q1 25 | 8.7% | -120.5% | ||
| Q4 24 | 1.2% | -48.3% | ||
| Q3 24 | -1.1% | -49.2% | ||
| Q2 24 | 12.4% | -53.7% | ||
| Q1 24 | 9.7% | -178.2% |
资本支出强度EVIRARE
| Q4 25 | — | 0.5% | ||
| Q3 25 | 1.8% | 0.8% | ||
| Q2 25 | 1.5% | 1.5% | ||
| Q1 25 | 1.1% | 1.0% | ||
| Q4 24 | 0.9% | 0.1% | ||
| Q3 24 | 1.3% | 1.2% | ||
| Q2 24 | 1.3% | 1.4% | ||
| Q1 24 | 1.5% | 3.0% |
现金转化率EVIRARE
| Q4 25 | 1.70× | — | ||
| Q3 25 | 0.55× | — | ||
| Q2 25 | 4.74× | — | ||
| Q1 25 | 8.79× | — | ||
| Q4 24 | 1.74× | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | 5.99× | — | ||
| Q1 24 | 9.85× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EVI
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
